Sign In
Buy AZN
$183.02
+2.00 (+1.10%)
At Close: Jun 24, 2026
AstraZeneca topples Shell as London's top dog but what about the "march of the makers"?
09:42am, Thursday, 07'th Apr 2022
With the share price of Shell PLC (LSE:SHEL, NYSE:SHEL) pulling back after today's trading update, AstraZeneca PLC (LSE:AZN) has cemented its position as Britain's most valuable company. Shell's marke
AstraZeneca has cracked a whole new cancer treatment market, but how much is worth?
08:38am, Thursday, 07'th Apr 2022
Research on AstraZeneca PLC (LSE:AZN) by JP Morgan underlined the scale of the opportunity on offer for the micro-cap life sciences companies developing the next wave of antibody-drug conjugate (ADC)�
The All-Weather Portfolio: The Good, The Bad, And The Ugly
06:06pm, Wednesday, 06'th Apr 2022 Seeking Alpha
The Financial Prophet's All-Weather Portfolio AWP delivered another solid quarter in Q1. Read the latest updates for the all-weather portfolio here.
AstraZeneca Expanding Digital Health Care, HART Invests
05:19pm, Wednesday, 06'th Apr 2022
AstraZeneca, a British pharmaceuticals giant and one of the major manufacturers of COVID-19 vaccines worldwide, has invested in Huma, a health start-up that provides software for doctors to monitor pa
AstraZeneca's Ultomiris Shows Sustained Improvements In Functional Activities In Neuromuscular Disease
11:47am, Wednesday, 06'th Apr 2022
AstraZeneca Plc (NASDAQ: AZN) shared new and prolonged follow-up results from the Phase 3 CHAMPION-MG trial open-label extension (OLE) of Ultomiris (ravulizumab-cwvz) in generalized myasthenia grav
Are AstraZeneca PLC shares a 'buy'? This leading bank is a fan
10:46am, Wednesday, 06'th Apr 2022
Providing an interesting take on the pharma sector was Deutsche Bank, which Wednesday raised its target price on AstraZeneca PLC (LSE:AZN). It pointed out (rightly) that a backdrop of rising inflatio
Clovis (CLVS) Up 24% on Upbeat Data From Ovarian Cancer Study
07:11pm, Monday, 04'th Apr 2022 Zacks Investment Research
Clovis Oncology's (CLVS) stock price rises after it reports favorable data from a late-stage study on Rubraca as the first-line maintenance treatment of ovarian cancer.
5 Top Health Care Stocks To Watch In The Stock Market Today
01:00pm, Sunday, 03'rd Apr 2022
Are these health care stocks on your watchlist right now?
2 Drugmakers Set for Explosive Revenue This Decade
10:00am, Sunday, 03'rd Apr 2022 The Motley Fool
They are selling much-needed products.
3 CEOs to Invest In
01:00am, Saturday, 02'nd Apr 2022 The Motley Fool
Looking for a healthcare stock with strong leadership? Our roundtable likes Immunocore, Axsome Therapeutics, and GlaxoSmithKline.
Pharma Stock Roundup: FDA Nod for 2nd COVID Booster, New Approvals for AZN, GSK, NVS
01:09pm, Friday, 01'st Apr 2022 Zacks Investment Research
FDA authorizes second booster dose of PFE and MRNA COVID-19 vaccines for older adults. RHHBY's late-stage study for ES-SCLC fails.
Adagio's (ADGI) COVID-19 Antibody Meets Goals in Studies
04:14pm, Thursday, 31'st Mar 2022 Zacks Investment Research
The stock price of Adagio (ADGI) surge after it reports positive preliminary data from the phase II/III studies, which evaluate its monoclonal antibody for the prevention and treatment of COVID-19.
Should You Buy Moderna? Look at These 2 Charts First.
10:00am, Tuesday, 29'th Mar 2022 The Motley Fool
They offer us clues about near-term and long-term revenue.
A Peek Into The Markets: US Stock Futures Higher Ahead Of Earnings, Fed Speakers
09:31am, Tuesday, 29'th Mar 2022 Benzinga
Pre-open movers
U.S. stock futures traded higher in early pre-market trade after the Dow Jones jumped around 150 points in the previous session. Investors are awaiting earnings results from McCormick
AstraZeneca's Ondexxya wins approval for reversal of acute major bleeds in patients
05:31am, Tuesday, 29'th Mar 2022
AstraZeneca PLC (LSE:AZN) said its Ondexxya treatment was approved in Japan, the first approved reversal agent specifically for Factor Xa inhibitors in the country. Ondexxya is a modified form of the
